logo
County Durham woman who lost 16 stone warns weight loss drugs aren't the answer

County Durham woman who lost 16 stone warns weight loss drugs aren't the answer

Yahoo3 days ago
A County Durham woman who lost 16 stone without drugs says she believes that slimming clubs are still needed despite the growing popularity of weight loss medication.
Starting in 2010, Sue Thompson lost 16 stone over two-and-a-half years by following Slimming World's eating plan.
Sue, from Chester-le-Street, now manages 145 Slimming World groups across County Durham and says that while weight loss injections such as Ozempic, Wegovy and Mounjaro have taken off as the quick solution to weight loss, lifestyle changes like those offered by her groups cannot be replaced.
Sue Thompson before her weight loss (Image: SUE THOMPSON)
She said: 'While, of course, I know first-hand that lasting weight loss can be achieved without drugs, I also understand that when you're desperate to lose weight, it can be tempting to try something new that promises instant results.
'I was 27 stone and 8lbs when I joined Slimming World and I used to fear that my weight would kill me, my health was impacted on a daily basis.
'The truth is though there's no magic bullet – losing weight and maintaining that weight loss requires change. Weight loss drugs need to go hand-in-hand with making changes to your diet, activity and mindset. They're not a replacement for those changes.'
Sue after her wight loss. She says there is no magic bullet to losing weight (Image: SUE THOMPSON)
With 64 million people in the UK overweight or living with obesity, Sue emphasised the importance of being part of a support group when trying to lose weight.
She said: 'Many people join our groups after trying to lose weight beforehand, often alone and unsuccessfully. They understand they need support because it isn't easy – and it's even harder on your own. Whether you're using weight loss medication or have had surgery, lasting change needs real support.
'Members form strong friendships in groups, and there's nothing quite like the motivation and accountability that comes from losing weight with others who understand the challenges.
Sue, before and after her weight loss, with her goddaughter, left, and a friend's baby, right (Image: SUE THOMPSON)
'Being part of a group helps you to stay on track and committed until the changes you're making become everyday habits.'
Weight loss drugs are more accessible than ever, although a poll of 2,000 adults revealed 69 per cent of adults would still be unlikely to take them. Of those, 25 per cent said they don't want to change the way they eat, drink and socialise, and 21 per cent worried they wouldn't get the nutrition they need for good health.
Most read:
The 'once extinct' bird of prey now thriving in the North East after sightings
Plans submitted for Grade I listed Bishop Auckland building that dates back to 1293
County Durham heritage venue earns national recognition in first year
Sue credits her healthy weight loss results to community-based slimming clubs.
She said: 'With Slimming World I lost weight with no deprivation or hunger and in a way that is for life.
'We will never judge anyone for going down the route of weight loss injections, we want them to know we are here with the support they need to make their weight loss sustainable.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management

Associated Press

time7 hours ago

  • Associated Press

Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management

SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2-4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: Wegovy Singapore Prescribing Information, February 2025Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: Obesity. Retrieved from World Obesity. Retrieved from I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at Health Organization. (2024). Obesity and As accessed on 22nd May J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit

Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

Yahoo

timea day ago

  • Yahoo

Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

Demand for Eli Lilly's LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company's key top-line drivers. In the first quarter of 2025, they generated combined sales of $6.15 billion, accounting for around 48% of Lilly's total revenues. Investors will be most keen to know the sales numbers of these two drugs when Lilly reports second-quarter results on Aug. 7. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025. The recovery was driven by launches of the drugs in new international markets and improved supply from ramped-up production. Earlier this year, the company launched additional lower-priced vial doses of Zepbound and offered new savings for self-pay patients to boost U.S. sales. We believe that deeper penetration in the U.S. market and increased uptake in international markets are likely to have driven the growth of both drugs in the second quarter of 2025. Our model estimates for second-quarter sales of Mounjaro and Zepbound are pegged at $4.5 billion and $3.1 billion, respectively. Beyond Mounjaro and Zepbound, Lilly's broader portfolio — including the oncology drug Verzenio and immunology drug Taltz — also continues to deliver steady growth. The company's recently launched drugs, such as Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience, have all been contributing to its top-line growth. According to a research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $100 billion by 2030. Eli Lilly and Novo Nordisk NVO presently dominate this space. Mounjaro and Zepbound directly compete with Novo Nordisk's semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Like Lilly, Novo also generates a substantial portion of revenues from both drugs, which account for around 64% of its total first-quarter sales. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the obesity space. Recently, Viking started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. A mid-stage study is currently ongoing, evaluating an oral version of this obesity drug, with a data readout expected later this year. Shares of Lilly have outperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 29.66 times forward earnings, higher than its industry's average of 15.16. However, the stock is trading below its five-year mean of 34.54. Image Source: Zacks Investment Research The bottom-line estimate for 2025 has remained consistent at $21.92, while that for 2026 has declined from $30.91 to $30.84 over the past 30 days. Image Source: Zacks Investment Research Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

'Expanding Horizons': Hims & Hers (HIMS) Brings Affordable Weight Loss Program to Canada
'Expanding Horizons': Hims & Hers (HIMS) Brings Affordable Weight Loss Program to Canada

Business Insider

time2 days ago

  • Business Insider

'Expanding Horizons': Hims & Hers (HIMS) Brings Affordable Weight Loss Program to Canada

Telehealth platform Hims & Hers Health (HIMS) has announced plans to launch its affordable weight loss program in Canada in 2026, marking its first entry into the country. The move coincides with the anticipated global launch of generic semaglutide, a lower-cost alternative to Novo Nordisk's (NVO) weight loss drugs, such as Ozempic and Wegovy. Following the news, HIMS stock gained about 1.5% on Wednesday morning. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. CEO Andrew Dudum called Canada a 'major opportunity.' About two-thirds of Canadian adults are overweight or obese, and often face high costs and limited access to effective treatments. Branded semaglutide, a proven weight loss medication, has historically been expensive as it costs over C$200 a month and often lacks medical support. Thus, Hims & Hers plans to use its digital platform to offer an affordable option, generic semaglutide. In addition, HIMS will provide 24/7 access to healthcare providers and custom care plans based on medical evidence. HIMS Global Expansion Moves The move comes after the recent acquisition of ZAVA, a digital health platform in Europe with a presence in Ireland, France, and Germany. This move is part of Hims & Hers' efforts to grow its international presence. By teaming up with ZAVA, Hims & Hers is expanding its offerings in dermatology, mental wellness, and weight management across multiple languages and healthcare systems. The company's CEO sees this expansion as a way to 'redefine accessible care at scale.' Overall, these expansion moves help the company strengthen its position as an international telehealth brand. Is HIMS Stock a Good Buy? Turning to Wall Street, HIMS stock has a Hold consensus rating based on one Buy, eight Holds, and two Sells assigned in the last three months. At $39.22, the average Hims & Hers stock price target implies a 20.69% downside potential.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store